The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Open accessAbstract
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-κB pathway. NF-κB is a key transcription factor, playing a role in the development and progression of cancer and chemoresistance through the activation of a multitude of mediators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signaling by pharmacological intervention will be addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 2×
“Upon binding to their cognate receptors, receptor associated Janus Kinases (JAKs) phosphorylate ligand-bound receptors resulting in the recruitment and activation of Signal Transducers and Activators of Transcription (STATs) (Darnell et al., 1994).”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Dose escalation of a curcuminoid formulation
Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., & Brenner, D. E. (2006) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-6-10 · Cited by 1,394
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0024 · Cited by 1,331
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · cited 1×
“Phosphorylated STATs form homodimers, localize to the nucleus, and regulate genes associated with apoptosis and proliferation (Darnell, 2002).”
BackgroundSuppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 893
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
NF-κB Signals Induce the Expression of c-FLIP
Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., & Tschopp, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5299-5305.2001 · Cited by 813
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
Role of NF-κB in p53-mediated programmed cell death
Ryan, K. M., Ernst, M. K., Rice, N. R., & Vousden, K. H. (2000) · Nature · doi:10.1038/35009130 · Cited by 740
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
The mitochondrial pathways of apoptosis
Estaquier, J., Vallette, F., Vayssiere, J.-L., & Mignotte, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_7 · Cited by 637
Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., & Nakshatri, H. (2007) · Oncogene · doi:10.1038/sj.onc.1209808 · Cited by 596
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling
Kreuz, S., Siegmund, D., Scheurich, P., & Wajant, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3964-3973.2001 · Cited by 583
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 517
Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition
Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., Dargemont, C., de Herreros, A. G., Bellacosa, A., & Larue, L. (2007) · Oncogene · doi:10.1038/sj.onc.1210546 · Cited by 476
Regulation of MAPKs by growth factors and receptor tyrosine kinases
Katz, M., Amit, I., & Yarden, Y. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.002 · Cited by 467
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., McFerran, B., Wyche, J., Kolch, W., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7207-7217.2001 · Cited by 387
Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB
Campbell, K. J., Rocha, S., & Perkins, N. D. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00131-5 · Cited by 386
Bush, J. A., Cheung, K.-J. J., & Li, G. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5381 · Cited by 385
Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., & Sarkar, F. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4604 · Cited by 376
Kane, R. C., Farrell, A. T., Sridhara, R., & Pazdur, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0170 · Cited by 341
Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B., & Diederich, M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.031 · Cited by 336
Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia
Vilimas, T., Mascarenhas, J., Palomero, T., Mandal, M., Buonamici, S., Meng, F., Thompson, B., Spaulding, C., Macaroun, S., Alegre, M.-L., et al. (2007) · Nature Medicine · doi:10.1038/nm1524 · Cited by 335
Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs
Micheau, O., Solary, E., Hammann, A., & Dimanche-Boitrel, M.-T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7987 · Cited by 320
CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response
Kato, T., Delhase, M., Hoffmann, A., & Karin, M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00358-7 · Cited by 314
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 312
Thévenod, F., Friedmann, J. M., Katsen, A. D., & Hauser, I. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.1887 · Cited by 301
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., & Bar-Sela, G. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.513802 · Cited by 282
Grandage, V. L., Gale, R. E., Linch, D. C., & Khwaja, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403653 · Cited by 281
Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., Dang, J., Zhu, S., Yang, H., De Jesus, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0124 · Cited by 275
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233739 · Cited by 269
Self-citationMiller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S., Shinn, P., Van Leer, D., Leister, W., Austin, C. P., & Xia, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.021 · Cited by 250
Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., Cheng, M.-H., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 210
Ariga, A., Namekawa, J.-I., Matsumoto, N., Inoue, J.-I., & Umezawa, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112063200 · Cited by 206
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209122 · Cited by 202
DNA repair: From molecular mechanism to human disease
Friedberg, E. C., Aguilera, A., Gellert, M., Hanawalt, P. C., Hays, J. B., Lehmann, A. R., Lindahl, T., Lowndes, N., Sarasin, A., & Wood, R. D. (2006) · DNA Repair · doi:10.1016/j.dnarep.2006.05.005 · Cited by 193
Snail is a repressor of RKIP transcription in metastatic prostate cancer cells
Beach, S., Tang, H., Park, S., Dhillon, A. S., Keller, E. T., Kolch, W., & Yeung, K. C. (2008) · Oncogene · doi:10.1038/sj.onc.1210860 · Cited by 189
NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type
Lin, B., Williams-Skipp, C., Tao, Y., Schleicher, M. S., Cano, L. L., Duke, R. C., & Scheinman, R. I. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400528 · Cited by 170
Yang, J., Amiri, K. I., Burke, J. R., Schmid, J. A., & Richmond, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1220 · Cited by 168
Kim, S.-J., Hwang, S.-G., Shin, D. Y., Kang, S.-S., & Chun, J.-S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202862200 · Cited by 168
Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition
Amiri, K. I., Horton, L. W., LaFleur, B., Sosman, J. A., & Richmond, A. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0673 · Cited by 167
NFκB Mediates Apoptosis through Transcriptional Activation of Fas (CD95) in Adenoviral Hepatitis
Kühnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., & Kubicka, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6421 · Cited by 163
Silke, J., Kratina, T., Chu, D., Ekert, P. G., Day, C. L., Pakusch, M., Huang, D. C. S., & Vaux, D. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502828102 · Cited by 161
Chuang, S.-E., Yeh, P.-Y., Lu, Y.-S., Lai, G.-M., Liao, C.-M., Gao, M., & Cheng, A.-L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00931-0 · Cited by 159
Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-κB
Fujioka, S., Schmidt, C., Sclabas, G. M., Li, Z., Pelicano, H., Peng, B., Yao, A., Niu, J., Zhang, W., Evans, D. B., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313435200 · Cited by 157
In vitro and in vivo anti‐tumoral effect of curcumin against melanoma cells
Odot, J., Albert, P., Carlier, A., Tarpin, M., Devy, J., & Madoulet, C. (2004) · International Journal of Cancer · doi:10.1002/ijc.20160 · Cited by 145
Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer
Annunziata, C. M., Stavnes, H. T., Kleinberg, L., Berner, A., Hernandez, L. F., Birrer, M. J., Steinberg, S. M., Davidson, B., & Kohn, E. C. (2010) · Cancer · doi:10.1002/cncr.25190 · Cited by 145
Yang, C. H., Gonzalez-Angulo, A. M., Reuben, J. M., Booser, D. J., Pusztai, L., Krishnamurthy, S., Esseltine, D. L., Stec, J. J., Broglio, K. R., Islam, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj131 · Cited by 141
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Tan, C., & Waldmann, T. A. (2002) · PubMed · Cited by 140
Bottero, V., Busuttil, V., Loubat, A., Magné, N., Fischel, J., Milano, G. A., & Peyron, J. (2001) · PubMed · Cited by 132
Pro-apoptotic role of NF-κB: Implications for cancer therapy
Radhakrishnan, S. K., & Kamalakaran, S. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.001 · Cited by 117
Zollo, M., Dato, V. D., Spano, D., Martino, D. D., Liguori, L., Marino, N., Vastolo, V., Navas, L., Garrone, B., Mangano, G., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9473-5 · Cited by 111
Bindarit: An anti-inflammatory small molecule that modulates the NFkB pathway
Mora, E. M., Guglielmotti, A., Biondi, G., & Sassone‐Corsi, P. (2012) · Cell Cycle · doi:10.4161/cc.11.1.18559 · Cited by 110
Lu, Z. H., Shvartsman, M. B., Lee, A. Y., Shao, J. M., Murray, M. M., Kladney, R. D., Fan, D., Krajewski, S., Chiang, G. G., Mills, G. B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3467 · Cited by 106
Zou, P., Kawada, J., Pesnicak, L., & Cohen, J. I. (2007) · Journal of Virology · doi:10.1128/jvi.02241-06 · Cited by 104
Anrather, J., Racchumi, G., & Iadecola, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409344200 · Cited by 102
Braeuer, S. J., Büneker, C. K., Mohr, A., & Zwacka, R. M. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0231 · Cited by 101
Baritaki, S., Yeung, K. C., Palladino, M. A., Berenson, J. R., & Bonavida, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1069 · Cited by 101
Wilson, C., Wilson, T. R., Johnston, P. G., Longley, D. B., & Waugh, D. J. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0148 · Cited by 100
Inhibition of tumor growth by NF‐κB inhibitors
Umezawa, K. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00285.x · Cited by 99
Protein interactions with platinum–DNA adducts: from structure to function
Chaney, S. G., Campbell, S. L., Temple, B. R. S., Bassett, E., Wu, Y., & Faldu, M. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.024 · Cited by 99
Cell Stress and MEKK1-mediated c-Jun Activation Modulate NFκB Activity and Cell Viability
Sánchez‐Pérez, I., Benitah, S. A., Martínez-Gomáriz, M., Lacal, J. C., & Perona, R. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-01-0022 · Cited by 98
Rivera-Walsh, I., Waterfield, M. R., Xiao, G., Fong, A., & Sun, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100501200 · Cited by 96
Fu, J., Jin, Y. H., & Arend, L. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308036200 · Cited by 91
Wuerzberger‐Davis, S. M., Nakamura, Y., Seufzer, B. J., & Miyamoto, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209815 · Cited by 90
The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer
Yang, G. S., Xiao, X., Rosen, D. G., Cheng, X., Wu, X., Chang, B., Liu, G., Xue, F., Mercado‐Uribe, I., Chiao, P. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3265 · Cited by 88
Meglio, P. D., Ianaro, A., & Ghosh, S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20960 · Cited by 87
Wu, Z., & Miyamoto, S. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.127 · Cited by 85
Yang, X.-H., Feng, Z., Yan, M., Hanada, S., Zuo, H., Yang, C., Han, Z.-G., Guo, W., Chen, W., & Zhang, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031601 · Cited by 84
Cisplatin Induces p53-Dependent FLICE-Like Inhibitory Protein Ubiquitination in Ovarian Cancer Cells
Abedini, M. R., Muller, É., Brun, J., Bergeron, R., Gray, D. A., & Tsang, B. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0673 · Cited by 83
Namba, R., Young, L. J. T., Abbey, C. K., Kim, L., Damonte, P., Borowsky, A. D., Qi, J., Tepper, C. G., MacLeod, C. L., Cardiff, R. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2170 · Cited by 81
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215617 · Cited by 81
Fury, M. G., Lee, N. Y., Sherman, E. J., Lisa, D., Kelly, K., Lipson, B. L., Carlson, D. L., Stambuk, H. E., Haque, S. S., Shen, R., et al. (2012) · Cancer · doi:10.1002/cncr.27498 · Cited by 79
p53 Gene Status Modulates the Chemosensitivity of Non-Small Cell Lung Cancer Cells
Lai, S., Perng, R.-P., & Hwang, J. (2000) · Journal of Biomedical Science · doi:10.1007/bf02255920 · Cited by 79
Molecular design and biological activities of NF-kappaB inhibitors.
Umezawa, K., & Chaicharoenpong, C. (2002) · PubMed · Cited by 67
Jennewein, C., Karl, S., Baumann, B., Micheau, O., Debatin, K., & Fulda, S. (2011) · Oncogene · doi:10.1038/onc.2011.333 · Cited by 65
NF-κB2 p100 is a pro-apoptotic protein with anti-oncogenic function
Wang, Y., Cui, H., Schroering, A. G., Ding, J., Lane, W. S., McGill, G. G., Fisher, D. E., & Ding, H. (2002) · Nature Cell Biology · doi:10.1038/ncb872 · Cited by 63
Kimura, M., Haisa, M., Uetsuka, H., Takaoka, M., Ohkawa, T., Kawashima, R., Yamatsuji, T., Gündüz, M., Kaneda, Y., Tanaka, N., et al. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401219 · Cited by 61
Tew, G. W., Lorimer, E., Berg, T. J., Zhi, H., Li, R., & Williams, C. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707526200 · Cited by 60
relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells
Ricca, A., Biroccio, A., Trisciuoglio, D., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2174 · Cited by 59
The Two Faces of NF?B in Cell Survival Responses
Graham, B. A., & Gibson, S. B. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2047 · Cited by 57
Barišić, S., Strozyk, E. A., Peters, N., Walczak, H., & Kulms, D. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.98 · Cited by 57
Takeuchi, H., Kim, J., Fujimoto, A., Umetani, N., Mori, T., Bilchik, A. J., Turner, R., Tran, A. N., Kuo, C. T., & Hoon, D. S. �. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0479 · Cited by 53
Function of Polo-like Kinase 3 in NF-κB-mediated Proapoptotic Response
Li, Z., Niu, J., Uwagawa, T., Peng, B., & Chiao, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410119200 · Cited by 51
Kuroda, H., Takeno, M., Murakami, S., Miyazawa, N., Kaneko, T., & Ishigatsubo, Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.015 · Cited by 50
Voortman, J., Smit, E. F., Honeywell, R. J., Kuenen, B. C., Peters, G. J., de Velde, H. J. V., & Giaccone, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0061 · Cited by 50
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells
Rogers, K., Thomas, M., Galligan, L., Wilson, T. R., Allen, W. L., Sakai, H., Johnston, P. G., & Longley, D. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0673 · Cited by 48
Allalunis‐Turner, M. J., Franko, A. J., & Parliament, M. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690328 · Cited by 43
Rae, C. J., Langa, S., Tucker, S. J., & MacEwan, D. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701437104 · Cited by 42
Enzler, T., Sano, Y., Choo, M., Cottam, H. B., Karin, M., Tsao, H., & Park, J. M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0143 · Cited by 38
Kamarajan, P., Sun, N., & Chao, C. C. ‐. (2003) · Biochemical Journal · doi:10.1042/bj20030659 · Cited by 37
Proapoptotic effects of NF-κB on cisplatin-induced cell death in auditory cell line
Chung, W., Boo, S. H., Chung, M. K., Lee, H.-S., Cho, Y., & Hong, S. H. (2008) · Acta Oto-Laryngologica · doi:10.1080/00016480701881811 · Cited by 36
Gomez-Abuin, G., Winquist, E., Stadler, W. M., Pond, G. R., Degendorfer, P., Wright, J., & Moore, M. J. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9009-4 · Cited by 34
Kulesza, D. W., Carré, T., Chouaïb, S., & Kaminska, B. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.11.005 · Cited by 31
Brown, R. E., & Law, A. (2006) · PubMed · Cited by 29
DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
MacFarlane, M., Jones, N. A., Dive, C., & Cohen, G. M. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09392-7 · Cited by 25
Epidermal Growth Factor and Trail Interactions in Epithelial-Derived Cells
Gibson, S. B. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67012-9 · Cited by 22
Hwang, S. G., Park, J., Park, J. Y., Park, C. H., Lee, K.-H., Cho, J. W., Hwang, J., & Seong, J. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044259 · Cited by 14
Lomonaco, S. L., Xu, X., & Wang, G. (2009) · DNA and Cell Biology · doi:10.1089/dna.2008.0815 · Cited by 13
Cited by
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Oral mucositis: the hidden side of cancer therapy
Pulito, C., Cristaudo, A., Porta, C. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01715-7 · Cited by 468
Pan, L., Feng, F., Wu, J., Fan, S., Han, J., Wang, S., Yang, L., Liu, W., Wang, C., & Xu, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106270 · Cited by 383
NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes
Suryavanshi, S. V., & Kulkarni, Y. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00798 · Cited by 348
Metadata
- Authors
- Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 120-120
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1976731794
- Cited by
- 296
- References
- 121
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.